[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Galzu Institute of Research, Teaching, Science and Applied Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100618500","efficacy-and-safety-of-alcovit-in-reducing-blood-alcohol-concentration-100618500",false,"NCT07332429","Efficacy and Safety of Alcovit in Reducing Blood Alcohol Concentration","Evaluation of the Efficacy and Safety of Alcovit (Zeolite Clinoptilolite) in Reducing Blood Alcohol Concentration in Healthy Individuals","Inclusion Criteria:\n\n* Healthy adults aged 18 to 70 years;\n* Occasional or moderate alcohol consumers;\n* Willing to abstain from alcohol and Alcovit® for a period established in the study;\n* Voluntary willingness to participate in the study and sign the Informed Consent Form (ICF);\n* Availability to comply with the study schedule.\n\nExclusion Criteria:\n\n* History of alcohol use disorder (alcoholism) or abuse of other illicit substances;\n* Hepatic, renal, gastrointestinal diseases, diabetes, and chronic conditions;\n* Use of medications that interact with alcohol, including but not limited to: non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen, diclofenac, naproxen), analgesics, antibiotics, antidepressants, benzodiazepines, anticoagulants, or any other medication that may interfere with alcohol metabolism or increase risks associated with alcohol consumption;\n* Pregnancy or breastfeeding (beta-hCG test will be performed);\n* Known allergy to any component of Alcovit® or placebo;\n* Patients already enrolled in other clinical trials;\n* Inability to provide free and informed consent;\n* Any clinically significant medical condition or medical history that, in the investigator's opinion, may discourage participation in the study.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},228,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if Alcovit® (zeolite clinoptilolite) works to reduce blood alcohol concentration in healthy adults aged 18-70 years who are occasional or moderate alcohol consumers. It will also learn about the safety and tolerability of Alcovit®. The main questions it aims to answer are:\n\n* Does Alcovit® reduce blood alcohol concentration when administered before or after standardized alcoholic beverage consumption compared to placebo?\n* What is the rate of alcohol elimination from the blood (mg\u002FdL\u002Fhour) in participants taking Alcovit® compared to placebo?\n* Is Alcovit® well tolerated when administered before or after alcohol consumption?\n\nResearchers will compare Alcovit® administered before alcohol consumption, Alcovit® administered after alcohol consumption, placebo administered before alcohol consumption, and placebo administered after alcohol consumption to see if Alcovit® effectively reduces blood alcohol levels.\n\nParticipants will:\n\n* Consume a standardized alcoholic beverage under controlled conditions;\n* Take Alcovit® or a placebo either 2-3 minutes before or after (within 5 minutes) alcohol consumption;\n* Have blood samples collected at baseline (30 minutes before), and at 20, 40, and 60 minutes after alcohol consumption to measure blood alcohol concentration;\n* Complete breathalyzer (etilometer) measurements at the same time points;\n* Answer questionnaire to assess alcohol hangover severity;\n* Have safety blood tests performed to monitor liver and kidney function.",[28,29,30],"Alcohol Drinking","Blood Alcohol Content","Hangover",[32,33,34,35,36,37],"Zeolite Clinoptilolite","Alcovit","Alcohol Absorption","Medical Device","Hangover Prevention","Blood Alcohol Concentration","NOT_YET_RECRUITING","2026-01-09",{"date":41,"type":42},"2026-01-12","ACTUAL",{"date":44,"type":22},"2026-05-30",{"date":46,"type":22},"2027-05-30",{"name":48,"class":49},"Galzu Institute of Research, Teaching, Science and Applied Technology","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":57,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100519593","vascular-supply-identification-lesion-extension-and-search-for-tumor-similarity-at-a-distance-by-vtm-in-breast-cancer-100519593","NCT06045572","Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer","Inclusion Criteria:\n\nWomen ≥18 years old; Women with breast cancer before oncological treatment; Voluntary signature of the Free and Informed Consent Term.\n\nExclusion Criteria:\n\nPregnant or lactating women; Patients already included in other clinical trials; Patients who are undergoing radiotherapy, chemotherapy or post-cancer surgery treatment; Patients who need urgent or emergency care; Patients with fever or other illness that affects the integrity of the skin; Any clinically significant medical condition or medical history that, in the opinion of the investigator, may discourage participation in the study.","FEMALE",{"count":59,"type":22},120,[25],"When we talk about early identification, we are talking about an ALREADY EXISTING INJURY, triggering a change in the patient's quality of life and a projection of future costs for the health system.\n\nINNOVATIVE ASPECT: While screening mammography identifies an existing lesion, VTM could: Make an early diagnosis before the formation of a visible or palpable tumor mass; Check the metabolic activity in suspicious lesions identified by other diagnostic methods; Demarcate tumor range and tumor similarity from a distance in breast cancer.\n\nRegarding the Risk x Benefit:There are no medications incorporated, associated or administered by the equipment; There is no ionizing radiation incorporated or delivered by the equipment; There are no contraindications for the use of the equipment by the patient (Non-ionizing infrared radiation, without contrast or contact); Audience destined to operate the equipment: Physician \u002F Radiologist with training Therefore, the research in question is of great relevance for such a debilitating health problem for the patient and for the health system.",[63],"Breast Cancer Female",{"date":41,"type":42},{"date":66,"type":22},"2026-06-01",{"date":68,"type":22},"2027-06-01",{"name":48,"class":49},""]